Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children.
about
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicActivities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection andMethicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseySystemic antibiotic therapy for chronic osteomyelitis in adultsManagement of community-associated methicillin-resistant Staphylococcus aureus infections in children.Toxin profiling of Staphylococcus aureus strains involved in varicella superinfection.Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, TexasClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolatesEvaluation of the automated Vitek 2 system for detection of various mechanisms of macrolide and lincosamide resistance in Staphylococcus aureus.Adherence to CLSI recommendations for testing of Staphylococcus aureus isolates in Louisiana hospitals: report of a clinical failure and results of a questionnaire study.Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates.MRSA USA300 at Alaska Native Medical Center, Anchorage, Alaska, USA, 2000-2006.Methicillin-resistant Staphylococcus aureus, Hawaii, 2000-2002.Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection.Community-associated methicillin-resistant Staphylococcus aureus in pediatric patientsCommunity-associated methicillin-resistant Staphylococcus aureus: a review.Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infectionsUSA300 Methicillin-Resistant Staphylococcus aureus, United States, 2000-2013.The emergence of severe, community-acquired methicillin-resistant Staphylococcus aureus infections.Community-acquired methicillin-resistant staphylococcus aureus: an emerging problem in the athletic population.Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.Community-associated meticillin-resistant Staphylococcus aureusDifferences in potential for selection of clindamycin-resistant mutants between inducible erm(A) and erm(C) Staphylococcus aureus genes.Epidemiological characteristics of methicillin-resistant Staphylococcus aureus isolates from children with eczematous atopic dermatitis lesions.Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners.The prevalence of inducible clindamycin resistance among staphylococci in a tertiary care hospital - a study from the garhwal hills of uttarakhand, IndiaCommunity-acquired methicillin-resistant Staphylococcus aureus skin infections: a review of epidemiology, clinical features, management, and prevention.Modes and modulations of antibiotic resistance gene expression.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Update on clindamycin in the management of bacterial, fungal and protozoal infections.Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic wavesCommunity-associated methicillin-resistant Staphylococcus aureus: trends in case and isolate characteristics from six years of prospective surveillance.Prevalence of inducible clindamycin resistance in staphylococcal isolates at a Korean tertiary care hospital.Treatment and recurrence management of staphylococcal infections: community-acquired MRSA.Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing.Community-associated Staphylococcus aureus infections in children.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.
P2860
Q24614464-29891BB4-939B-45A4-9821-48D8E9642D68Q24643277-E8CC50A4-A7C6-47A4-AC69-0942E7C0B1AAQ28235095-04DA96D5-C428-4EC2-B43C-B7D922FA7059Q28714211-2E079945-5223-4D09-98AB-8AB6483C844BQ33264579-24CB45D6-A043-453D-A6CC-AE0531637F89Q33827292-274F9541-E59B-4333-B892-0E4E3BF71948Q33836641-EA715C61-C523-45B1-80A1-2F9A510BB491Q34157657-61EA7B0C-1894-44EC-B138-DB1775081DB1Q34719746-D3297859-A019-4722-80CF-BE463A47BA28Q35036119-BAE1633E-30F5-46E1-B7BF-5F06EA6AC70AQ35139881-04899159-E189-4194-AE71-27F1E362535CQ35805583-97F6442B-D7A1-4DE9-833C-8BBB8870BF7AQ35845890-6CDF3C26-E017-4FBE-8CEB-187111C240DAQ35873382-05603C80-0255-4A25-B6C8-F24A5210CDC8Q35913984-BE2F21EF-C42F-4EBE-83C4-D8B03C51B313Q36009370-8F9FD0FE-7466-4757-AF7D-DEF89766CC92Q36070903-DE37280E-C801-49A4-AB59-467D88C1B292Q36071256-E885A083-E7D0-4497-BE49-A8343976A5B6Q36212072-E77E73C2-DD95-4540-A13D-6445D48F2552Q36242617-CEBE939E-E374-46EE-9F28-5FDF94D84E8CQ36325494-0B3ACB77-F543-44E1-820B-3680AA10EE78Q36379346-8DFD975E-D28F-41E7-B818-AA0334882A70Q36409465-D9216A1C-858D-4CD4-8CF2-38EA57D8BCBCQ36438720-4A4ED6A8-B370-4DDE-9355-D9E980E1B6B5Q36452596-41030302-073C-4D55-A577-5F39A970DA72Q36497964-7A2AA7EB-6958-4D22-80C3-20CAC03E98C1Q36563779-6A7B237E-6617-4E77-86A7-7A8653340454Q36622487-4A72CDAE-EB47-4BEF-92E7-7476E50294BBQ36703883-D97CB773-0750-454E-9B4B-DAD274E68C78Q36708242-BC9BAB5B-1673-4E5C-A5A4-8825CCBDB6CFQ36718474-51AE0908-C2EF-44FA-AC0E-284395B4C9A5Q36758570-697AB04C-5D6C-4DAB-A623-C2CB8A745BF5Q36967293-59F41E39-63AB-49B6-B440-D69193926F79Q36999966-2D72DF5E-8F4A-49D8-A37B-FCBB88C0D87EQ37146565-1C9E4F84-AAD4-4473-98E6-BBFFF5608F5CQ37205609-F757F208-0062-4D4D-816A-E2B1E41B935CQ37340558-9817A31B-E29D-4F44-B10A-224868F61201Q37421099-46C65DB3-4F56-495B-8418-77CBD20198B8Q37747396-C44AA710-88E8-45A1-B6C2-A493498DCB13Q37800939-8EDF14FE-C97A-4D18-870F-3747849A7562
P2860
Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Clindamycin treatment of methi ...... aureus infections in children.
@en
Clindamycin treatment of methi ...... aureus infections in children.
@nl
type
label
Clindamycin treatment of methi ...... aureus infections in children.
@en
Clindamycin treatment of methi ...... aureus infections in children.
@nl
prefLabel
Clindamycin treatment of methi ...... aureus infections in children.
@en
Clindamycin treatment of methi ...... aureus infections in children.
@nl
P2093
P1476
Clindamycin treatment of methi ...... aureus infections in children.
@en
P2093
Arthur L Frank
John F Marcinak
John P Quinn
Joyce T Tjhio
P Daisy Mangat
Paul C Schreckenberger
Swathi Kelkar
P304
P356
10.1097/00006454-200206000-00010
P577
2002-06-01T00:00:00Z